Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Core Insights - Senti Biosciences, Inc. is focused on advancing its SENTI-202 clinical development for relapsed/refractory acute myeloid leukemia (AML), with significant milestones achieved in Q3 2025 [2][3] - The company plans to present updated clinical data at the upcoming ASH Annual Meeting, emphasizing the efficacy and safety of its Logic Gate technology [2][7] Financial Results - As of September 30, 2025, Senti Bio reported cash and cash equivalents of approximately $12.2 million, a decrease from $48.3 million as of December 31, 2024 [7][13] - Research and development expenses for Q3 2025 were $10.5 million, up from $8.7 million in Q3 2024, primarily due to increased external services and personnel-related costs [7][14] - General and administrative expenses decreased slightly to $6.4 million in Q3 2025 from $6.6 million in Q3 2024 [7][14] - The net loss for Q3 2025 was $18.1 million, or $0.69 per share, compared to a net loss of $28.9 million in Q3 2024 [7][15] Pipeline and Corporate Highlights - The company is actively enrolling additional patients for the SENTI-202 trial and has achieved important milestones in its dose expansion phase [2][3] - Senti Bio's Gene Circuit platform is designed to enhance precision in targeting cancer cells while sparing healthy tissue, addressing a significant challenge in cancer treatment [6][8] - The company has participated in various investor conferences to increase market awareness and visibility among the scientific community [4][7]